ranolazine


( Last Updated : May 31, 2021)
Generic Name:
ranolazine
Project Status:
Active
Therapeutic Area:
Stable angina pectoris, adults
Manufacturer:
KYE Pharmaceuticals Inc.
Brand Name:
Corzyna
Project Line:
Reimbursement Review
Project Number:
SR0655-000

Details


Manufacturer Requested Reimbursement Criteria1:
Indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers.
Recommendation Type:
Do not reimburse
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openJuly 17, 2020
Call for patient input closedSeptember 08, 2020
Clarification:

- No patient input submission received

Submission receivedAugust 17, 2020
Submission acceptedAugust 31, 2020
Review initiatedSeptember 01, 2020
Clarification:

- Selected for CADTH/INESSS Joint Clinician Engagement

Draft CADTH review report(s) provided to sponsor for commentNovember 17, 2020
Deadline for sponsors commentsNovember 26, 2020
CADTH responses on draft review report(s) provided to sponsorJanuary 08, 2021
CADTH review report(s) and responses to comments provided to sponsorJanuary 08, 2021
Expert committee meeting (initial)January 20, 2021
Draft recommendation issued to sponsorFebruary 01, 2021
End of embargo periodFebruary 16, 2021
Clarification:

- Reconsideration requested

Expert committee meetingMay 19, 2021
Final recommendation issued to sponsor and drug plansMay 27, 2021
Final recommendation postedMay 31, 2021
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)June 10, 2021